H.C. Wainwright lowered the firm’s price target on AngioDynamics to $18 from $20 and keeps a Buy rating on the shares. The company reported mixed results in fiscal Q2 as it transitions to outsourced manufacturing, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANGO:
- AngioDynamics down 10% at $7.00 after Q2 revenue miss, FY24 guidance cut
- AngioDynamics cuts FY24 EPS view to (42c) to (35c) from (34c) to (28c)
- AngioDynamics reports Q2 EPS (5c), consensus (7c)
- Options Volatility and Implied Earnings Moves Today, January 05, 2024
- Options Volatility and Implied Earnings Moves This Week, January 03 – January 05, 2024
